Corrigendum to “Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment” [Schizophr. Res. 154 (1–3) (2014) 23–29]

2014 ◽  
Vol 157 (1-3) ◽  
pp. 321
Author(s):  
Lot de Witte ◽  
Jakub Tomasik ◽  
Emanuel Schwarz ◽  
Paul C. Guest ◽  
Hassan Rahmoune ◽  
...  
Keyword(s):  
First Episode ◽  
Antipsychotic Treatment ◽  
Before And After ◽  
First Episode Schizophrenia

scholarly journals An fMRI study of visual attention and sensorimotor function before and after antipsychotic treatment in first-episode schizophrenia

2009 ◽  
Vol 172 (1) ◽  
pp. 16-23 ◽  
Author(s):  
Sarah K. Keedy ◽  
Cherise Rosen ◽  
Tin Khine ◽  
Rajaprabhakaran Rajarethinam ◽  
Philip G. Janicak ◽  
...  
Keyword(s):  
Visual Attention ◽  
First Episode ◽  
Antipsychotic Treatment ◽  
Sensorimotor Function ◽  
Fmri Study ◽  
Before And After ◽  
First Episode Schizophrenia

scholarly journals Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment

2014 ◽  
Vol 154 (1-3) ◽  
pp. 23-29 ◽  
Author(s):  
Lot de Witte ◽  
Jakub Tomasik ◽  
Emanuel Schwarz ◽  
Paul C. Guest ◽  
Hassan Rahmoune ◽  
...  
Keyword(s):  
First Episode ◽  
Antipsychotic Treatment ◽  
Before And After ◽  
First Episode Schizophrenia

scholarly journals The Effects of Antipsychotic Treatment on the Brain of Patients With First-Episode Schizophrenia: A Selective Review of Longitudinal MRI Studies

2021 ◽  
Vol 12 ◽  
Author(s):  
Chengmin Yang ◽  
Jing Tang ◽  
Naici Liu ◽  
Li Yao ◽  
Mengyuan Xu ◽  
...  
Keyword(s):  
Functional Imaging ◽  
Term Treatment ◽  
First Episode ◽  
Antipsychotic Treatment ◽  
Imaging Studies ◽  
Temporal Lobes ◽  
Long Term Treatment ◽  
Before And After ◽  
First Episode Schizophrenia ◽  
The Brain

A large number of neuroimaging studies have detected brain abnormalities in first-episode schizophrenia both before and after treatment, but it remains unclear how these abnormalities reflect the effects of antipsychotic treatment on the brain. To summarize the findings in this regard and provide potential directions for future work, we reviewed longitudinal structural and functional imaging studies in patients with first-episode schizophrenia before and after antipsychotic treatment. A total of 36 neuroimaging studies was included, involving 21 structural imaging studies and 15 functional imaging studies. Both anatomical and functional brain changes in patients after treatment were consistently observed in the frontal and temporal lobes, basal ganglia, limbic system and several key components within the default mode network (DMN). Alterations in these regions were affected by factors such as antipsychotic type, course of treatment, and duration of untreated psychosis (DUP). Over all we showed that: (a) The striatum and DMN were core target regions of treatment in schizophrenia, and their changes were related to different antipsychotics; (b) The gray matter of frontal and temporal lobes tended to reduce after long-term treatment; and (c) Longer DUP was accompanied with faster hippocampal atrophy after initial treatment, which was also associated with poorer outcome. These findings are in accordance with previous notions but should be interpreted with caution. Future studies are needed to clarify the effects of different antipsychotics in multiple conditions and to identify imaging or other biomarkers that may predict antipsychotic treatment response. With such progress, it may help choose effective pharmacological interventional strategies for individuals experiencing recent-onset schizophrenia.

scholarly journals Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia

2007 ◽  
Vol 191 (4) ◽  
pp. 325-334 ◽  
Author(s):  
Jean Théberge ◽  
Kate E. Williamson ◽  
Naoko Aoyama ◽  
Dick J. Drost ◽  
Rahul Manchanda ◽  
...  
Keyword(s):  
Temporal Lobe ◽  
Grey Matter ◽  
Anterior Cingulate ◽  
First Episode ◽  
Antipsychotic Treatment ◽  
Plastic Response ◽  
Number Of Factors ◽  
Before And After ◽  
First Episode Schizophrenia ◽  
Healthy Participants

BackgroundProgressive volumetric changes in the brains of people with schizophrenia have been attributed to a number of factors.AimsTo determine whether glutamatergic changes in patients with schizophrenia correlated with grey-matter losses during the first years of illness.MethodLeft anterior cingulate and thalamic glutamatergic metabolite levels and grey-matter volumes were examined in 16 patients with first-episode schizophrenia before and after 10 months and 30 months of antipsychotic treatment and in 16 healthy participants on two occasions 30 months apart.ResultsHigher than normal glutamine levels were found in the anterior cingulate and thalamus of never-treated patients. Thalamic levels of glutamine were significantly reduced after 30 months. Limited grey-matter reductions were seen in patients at 10 months followed by widespread grey-matter loss at 30 months. Parietal and temporal lobe grey-matter loss was correlated with thalamic glutamine loss.ConclusionsElevated glutamine levels in never-treated patients followed by decreased thalamic glutamine and grey-matter loss in connected regions could indicate either neurodegeneration or a plastic response to reduced subcortical activity.

scholarly journals The Side Effect of Haloperidol in Schizophrenic Patients: Analysis of Red Blood Cell Distribution Width (RDW) and Mean Platelet Volume (MPV) Values

2019 ◽  
Vol 11 (2) ◽  
pp. 55
Author(s):  
Andi Jayalangkara Tanra ◽  
Hawaidah Hawaidah ◽  
Yazzit Mahri ◽  
Saidah Syamsuddin ◽  
Andi Nilawati Usman ◽  
...  
Keyword(s):  
Side Effect ◽  
First Episode ◽  
Distribution Width ◽  
Before And After ◽  
Icd 10 ◽  
Schizophrenic Patients ◽  
Haloperidol Treatment ◽  
Analytic Design ◽  
First Episode Schizophrenia ◽  
Haloperidol Group

INTRODUCTION: Like the increase of pro-inflammatory cytokines and oxidative stress as schizophrenia pathophysiology, haloperidol also increases RDW and MPV values. Both of these values ​​have been clinicians concern because they are a risk factor for the various type of vascular disease. OBJECTIVE: This study aims to determine the side effect of haloperidol on RDW and MPV values in schizophrenic patients. METHODS: This research method uses observational analytic design with a prospective cohort approach with pre and posts analysis conducted at the Regional Special Hospital of South Sulawesi Province during May - July 2018 in 30 schizophrenic subjects. The subjects were diagnosed as first episode schizophrenia based on ICD 10, blood samples were taken, for RDW and MPV values ​​before and after haloperidol was given at the 4th and 8th weeks. RESULTS: The results showed that the mean RDW value at the 4th week was higher in 15 mg/day haloperidol group (15.8) compared to 7.5 mg/day haloperidol group (15.3) with p<0.05. Mean RDW value taken at 8th week was higher in 15 mg/day haloperidol group (16.4) compared to 7.5 mg/day haloperidol group (15.6) with p<0.001. Mean MPV value taken at 8th week was higher in 15 mg/day haloperidol group (13.3) compared to 7.5 mg/day haloperidol group (11.6) with p<0.001. CONCLUSION: This study showed an increase in the RDW value in schizophrenia subjects prior to the haloperidol administration. RDW ​​and MPV values were higher after haloperidol treatment compares to before haloperidol treatment. The increase of RDW and MPV values tend to be influenced by haloperidol dosage and administration duration.

Changes in the cytokine profile in first episode, drug-naïve patients with psychosis after short-term antipsychotic treatment

2017 ◽  
Vol 41 (S1) ◽  
pp. S371-S371
Author(s):  
P. Petrikis ◽  
P. Voulgari ◽  
V. Boumba ◽  
D. Archimandriti ◽  
P. Skapinakis ◽  
...  
Keyword(s):  
Antipsychotic Medication ◽  
Transforming Growth Factor ◽  
Serum Levels ◽  
Psychotic Symptoms ◽  
First Episode ◽  
Enzyme Linked Immunosorbent Assay ◽  
Antipsychotic Treatment ◽  
Before And After ◽  
Drug Naïve ◽  
Competing Interest

IntroductionAn increasing body of evidence suggests that antipsychotic medication can cause immunological changes that could be attributed to the amelioration of psychotic symptoms or the metabolic side effects of the drugs. So far, the results of the studies remain controversial.ObjectiveOur aim was to compare the levels of interleukin (IL) IL-2, IL-6 and transforming growth factor-β2 (TGF-β2) in drug-naïve, first-episode patients with psychosis before and after six weeks of antipsychotic medication.MethodsThirty-nine first episode patients with psychosis were enrolled in the study. Serum levels of IL-2, IL-6 and TGF-β2 were measured by enzyme linked immunosorbent assay (ELISA) before and six weeks after the initiation of antipsychotic medication. In addition, clinical psychopathology was assessed using Positive and Negative Syndrome Scale (PANSS) before and after treatment.ResultsSerum levels of IL-2 were significantly higher in the study group six weeks after the initiation of antipsychotic treatment (P < 0.001) while TGF-β2 levels were decreased (P < 0.001) and IL-6 levels were slightly reduced (P < 0.004).ConclusionThe changes in cytokine levels may be attributed to the action of antipsychotic medication and the remission of psychopathology. The reduction in TGF-β2 levels is observed in all patients and with all antipsychotic medications used. TGF-β2 may be a marker of clinical efficacy.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial

2013 ◽  
Vol 16 (5) ◽  
pp. 987-995 ◽  
Author(s):  
W. Wolfgang Fleischhacker ◽  
Cynthia O. Siu ◽  
Robert Bodén ◽  
Elizabeth Pappadopulos ◽  
Onur N. Karayal ◽  
...  
Keyword(s):  
Risk Factors ◽  
General Population ◽  
Prevalence Rate ◽  
Individual Risk ◽  
First Episode ◽  
Antipsychotic Treatment ◽  
Treatment Groups ◽  
Individual Risk Factors ◽  
First Episode Schizophrenia

Abstract Available data on antipsychotic-induced metabolic risks are often constrained by potential confounding effects due to prior antipsychotic treatment. In this study, we assessed the baseline prevalence of metabolic abnormalities and changes following treatment with five commonly-used antipsychotic drugs (haloperidol, amisulpride, olanzapine, quetiapine or ziprasidone) in first-episode, partially antipsychotic-naive patients with schizophrenia in the European first-episode schizophrenia trial (EUFEST). Overall baseline prevalence of metabolic syndrome (MetS) was 6.0%, with similar rates observed in the antipsychotic-naive patients (5.7%, 9/157) and in the other patients with only a brief prior exposure to antipsychotics (6.1%, 20/326). These results are consistent with the MetS prevalence rate estimated in a general population of similar age. Examination of individual risk factors showed 58.5% of subjects had one or more elevated metabolic risks at baseline: 28.5% demonstrated suboptimal HDL; 24.2% hypertension; 17.7% hypertriglyceridemia; 8.2% abdominal obesity; 7.3% hyperglycaemia. Increase in body weight (kg/month) occurred in patients treated with haloperidol (0.62 s.e. 0.11), amisulpride (0.76 s.e. 0.08), olanzapine (0.98 s.e. 0.07) and quetiapine (0.58 s.e. 0.09), which was significantly greater than that in the ziprasidone group (0.18 s.e. 0.10). The incidence rate of new diabetes cases over a 52-wk follow-up period was 0.82% (4/488). More patients experienced worsening rather than improvement of hypertriglyceridemia or hyperglycaemia in all treatment groups. Our findings suggest that in first-episode, partially antipsychotic-naive patients, the baseline prevalence rate of MetS appears to be no higher than that in the general population, but serious underlying individual risk factors nevertheless existed.

Sign in / Sign up

Export Citation Format

Share Document